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Abstract
Hodgkin lymphoma (HL) represents a category of lymphoid neoplasms with unique features, notably the usual
scarcity of tumour cells in involved tissues. The most common subtype of classical HL, nodular sclerosis HL,
characteristically comprises abundant fibrous tissue stroma. Little information is available about the protein
composition of the stromal environment from HL. Moreover, the identification of valid protein targets, specifically
and abundantly expressed in HL, would be of utmost importance for targeted therapies and imaging, yet the
biomarkers must necessarily be accessible from the bloodstream. To characterize HL stroma and to identify
potentially accessible proteins, we used a chemical proteomic approach, consisting in the labelling of accessible
proteins and their subsequent purification and identification by mass spectrometry. We performed an analysis of
potentially accessible proteins in lymph node biopsies from HL and reactive lymphoid tissues, and in total, more
than 1400 proteins were identified in 7 samples. We have identified several extracellular matrix proteins
overexpressed in HL, such as versican, fibulin-1, periostin, and other proteins such as S100-A8. These proteins were
validated by immunohistochemistry on a larger series of biopsy samples, and bear the potential to become targets
for antibody-based anti-cancer therapies.
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Background
Human malignant lymphomas encompass a large variety
of lymphoid neoplasms, that broadly are classified as
Hodgkin lymphomas (HL) or non-Hodgkin lymphomas
(NHL). One of the hallmark features of classical HL is
the relative scarcity of typically large or giant neoplastic
cells (Reed-Sternberg cells and variants), dispersed
within an abundant mixed reactive cellular infiltrate and
associated with a variably prominent stroma [1].
Importantly, bidirectional interactions involving soluble
factors and membrane-bound receptors are known to take
place between Reed-Sternberg cells and the various types
of surrounding non-neoplastic cells, and the reactive com-
ponent of HL tissues is suspected to play a major role in
sustaining tumour development and progression [2]. In
addition, the stromal compartment of many neoplastic
tissues is fundamentally different from that of the corre-
sponding normal tissue, and is suspected to promote
cancer progression [3]. In this respect, little is known
about the composition of the extracellular matrix (ECM)
of HL. A comprehensive determination of the composition
of the stromal compartment in HL appears therefore
essential for a better understanding of the disease, and
could lead to the discovery of new diagnostic and thera-
peutic markers allowing earlier detection and treatment of
relapsed and refractory HL. Recurrent and refractory HL
remain indeed an unmet challenge, and new strategies to
improve outcome and reduce complications after standard
therapy are required.
The use of gene microarrays can provide valuable infor-
mation about the regulation of gene expression [4]. How-
ever, it has become increasingly evident over the past
decade that mRNA quantitation does not always reflect
corresponding protein levels [5,6]. In this context, pro-
teome analyses provide a direct snapshot of the structural
and functional framework of cellular life, and remain the
best way to characterize a cellular environment and to
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used to identify protein markers in lymphoma include
enzyme-linked immunosorbent assays (ELISA), immuno-
histochemistry (IHC) on tissue microarrays, and mass-
spectrometry (MS). However, proteomic analyses of
human lymphoma are still very limited, and most of the
studies were conducted on cell lines [7-9]. Only scarce
data from high-throughput proteomic data are currently
available for human nodular sclerosis HL tissues [10],
while data are available for human NHL tissues, including
mantle cell lymphoma [11-13], diffuse large B-cell lym-
phoma [14], small lymphocytic lymphoma and marginal
zone lymphoma [13].
Herein, we performed an analysis of potentially accessi-
ble proteins in human HL (n = 4), in comparison to
benign lymphoid tissue (reactive lymphoid hyperplasia,
RLH, n = 3). To this end, we used a recently described
chemical proteomic technology [15], which permits the
identification of accessible antigens through biotinylation
of exposed primary amines. This technique allowed us to
analyse, among others, the ECM proteins of our samples.
Overall, over 1430 proteins were identified in all HL or
RLH tissues. We found differentially expressed ECM pro-
teins in HL, such as versican, fibulin-1, periostin, and
other proteins such as S100-A8. These proteins were vali-
dated by immunohistochemistry and may become poten-
tial targets for either diagnostic or therapeutic purposes.
Results
Validation of the biotinylation step
The biotinylation protocol that was applied is summar-
ized in Figure 1. The biotinylation protocol was applied
to 4 classical HL samples (all samples being nodular
sclerosis HL) and 3 lymph nodes with reactive lymphoid
hyperplasia (RLH). All clinico-pathological characteristics
are described in Table 1 and Table 2. Biotinylation was
carried out to allow subsequent purification of accessible
proteins. In order to assess adequacy of the biotin label-
ling, a representative sample of each biotinylated tissue
was analysed by histochemistry with avidin-peroxidase
conjugates (Figure 2). A strong staining was found in the
stroma and at the cell surface in biotinylated tissues
(Figure 2B). Negative control experiments in which tis-
sues were soaked in PBS did not show any reactivity.
Mass spectrometry analyses
Expression profiles of biotinylated, accessible proteins
were determined using the Multidimensional Protein
Identification Technology (MudPIT) technique, based
on 2-dimensional separation of tryptic peptide digest
using nanoflow liquid chromatography coupled to elec-
trospray tandem mass spectrometry. Each run consisted
in the complete analysis in mass spectrometry of one
sample.
Considering these 7 2D-LC runs, 551 ± 35 proteins
were identified in each sample (mean ± SEM). Pie-charts
representing the distribution of identified proteins
among RLH and HL are shown in Additional File 1. Our
comparative analysis of RLH versus HL nodal tissues
identified several proteins known to be preferentially
localized at the cell membrane or in the extracellular
compartment (almost 30%). Of particular interest are
those proteins overexpressed in HL. Table 3 shows a
selection of 9 accessible proteins identified from biotiny-
lated samples (see Additional File 2 for the full protein
list). This selection of relevant proteins is based 1) on the
regulation of the proteins (up- or down-regulation) and
2) on the actual presence of the protein either in the
membrane fraction or in the extracellular space. Regula-
tion was assessed by both “on-off” and spectral counting
methods: for each analysis, a given protein was present or
absent ("on” or “off”). Whenever present, we used the
associated spectral counting (i.e. the number of redun-
dant spectra of the same peptide) as a quantification
mean [16], in order to have an idea of the relative protein
abundance in the samples. Spectral counts for each pro-
tein are reported in Additional File 2.
Finally, in order to assess the specificity of the streptavidin
column, non-biotinylated lymphoma samples were also
processed and analysed by MS. In this latter case, the
recovery after elution was negligible (~40X less than the
average recovery from biotinylated tissues, 100 mg starting
material in both conditions), and the first ten proteins
identified were cytokeratins (most probably “contaminat-
ing” proteins that stuck to the streptavidin beads), showing
unambiguously the specificity of our approach.
We turned our interest onto versican, fibulin-1, perios-
tin and S100A8 proteins, because no direct relationships
with HL were previously established in the literature for
these proteins. Versican was identified in only two HL
(out of 4), but we had learned from previous experiments
that identification of peptides from this protein in com-
plex mixtures may be difficult [15]. Therefore, we sus-
pected that versican could be expressed in a higher
proportion of diseased tissues (the same assumption
applied to fibulin-1, known to interact with the versican).
Since versican and fibulin peptides are potentially diffi-
cult to detect in complex mixtures using mass spectro-
metry (because they are large, heavily glycosylated
proteins), and because of their implication in cancer, we
decided to further validate these two ECM proteins using
IHC. More evidently, two other markers were clearly
overexpressed in HL compared to RLH: periostin and
S100A8.
Validation of the potential targets
Three proteins, namely versican, fibulin-1, and periostin
are extracellular matrix proteins.
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Page 2 of 11Figure 1 Schematic description of the method used in this study for the identification of accessible proteins in Hodgkin lymphoma
and reactive lymph nodes. Ex vivo biotinylation of human tissue samples was carried out by incubating fresh tissues in a solution containing
reactive ester derivatives of biotin. Proteins from each tissue sample were extracted. Biotinylated proteins were then captured on streptavidin
resin, eluted thanks to the disulfide bond between the lysines and the biotin, alkylated and submitted to proteolytic digestion. Biotinylated
proteins were sequenced by shotgun mass spectrometry using nLC-ESI MS/MS. Identified proteins differentially expressed in the tissue samples
were further validated by immunohistochemical analysis.
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Versican, a large chondroitin-sulfate proteoglycan,
mainly secreted by stromal cells in the ECM, is a recog-
nized cell adhesion and motility modulator that may
facilitate tumour cell invasion and metastasis [17].
While versican expression in reactive lymph nodes was
generally absent (Figure 3A), moderate to strong immu-
noreactivity was observed in the stromal compartment
of 13 out of the 17 HL tissues analysed. Fibrous bands
of stroma were strongly stained (Figure 3B), and strong
perivascular staining was also observed in some HL
cases.
Table 1 Clinico-pathological characteristics of the Reactive Lymphoid Hyperplasia (RLH) analysed in the study
Intensity of immunostaining
n° age sex size (cm) Localisation subtype CD30 CD15 EBV Versican Fibulin-1 Periostin
RLH1 47 F 0,7 inguinal benign lymph node / / / - -/+ -/+
RLH2 68 M 1,3 inguinal benign lymph node / / / - -/+ +
RLH3 87 M 0,9 internal mammary chain benign lymph node - / / - - -/+
RLH4 59 M 2 axillary follicular hyperplasia +/- -- - -/+ -/+*
RLH5 38 M 1,3 cervical follicular hyperplasia / / / - - -/+
RLH6 24 M 1,8 axillary follicular hyperplasia +/- / - - - +
RLH7 62 F 0,7 axillary follicular hyperplasia / / / - - +
RLH8 22 M 1,2 spinal follicular hyperplasia / / / - - +
RLH9 22 M 1,9 submaxillary mixed lymphoid hyperplasia -- / - -/+ -
RLH10 28 M 1,9 cervical mixed lymphoid hyperplasia / / - + -/+ ++
RLH11 46 F 1,7 inguinal mixed lymphoid hyperplasia - / - -/+ -/+ ++
RLH12 38 F 1,3 subdigastric mixed lymphoid hyperplasia / / / - + ++
RLH13 39 F 0,9 supraclavicular mixed lymphoid hyperplasia +/- / / -/+ -/+ ++
RLH14 24 F 0,5 cervical sarcoidosis / / / - -/+ +
RLH15 57 M 1,5 mediastinal sarcoidosis / / / - - +
Scoring of the intensity of the staining for fibulin-1, periostin and versican was performed as described in the “Methods” section. Cases in bold were analysed by
mass spectrometry (see Additional File 2). The asterisk indicates that the protein was also detected by mass spectrometry in the same sample.
Table 2 Clinico-pathological characteristics of the nodular sclerosis Hodgkin Lymphoma (HL) analysed in the study
Intensity of immunostaining
n° age sex size (cm) nature of lymph node CD30 CD15 EBV Versican Fibulin-1 Periostin
HL1 19 M 1,3 cervical + + - +++ +++ ++*
HL2 45 M 1,7 cervical + + + ++* + +++*
HL3 21 F 2,6 axillary + + - -/+ ++* ++*
HL4 27 M 2,2 cervical + +/- - ++* ++* +++*
HL5 17 F 2,4 cervical + + - +++ + ++
HL6 16 F 1,6 jugular + - - +++ +++ +++
HL7 21 M 1,5 supraclavicular + - - +++ +++ +++
HL8 27 M 3,8 axillary +/- +/- - +++ +++ +++
HL9 29 M 1 cervical + + - +++ +++ +++
HL10 31 M 1,5 mediastinal + + - ++ ++ +++
HL11 19 F 2,5 cervical + +/- - ++ ++ +++
HL12 33 M 2,1 cervical + +/- + +++ +++ +++
HL13 37 F 2,5 supraclavicular + +/- - ++ ++ +++
HL14 22 F 0,8 cervical + +/- - + -/+ +++
HL15 20 M 3,1 cervical + +/- + + - ++
HL16 54 M 1 cervical + + + -/+ - ++
HL17 33 F 1 supraclavicular + + - +++ ++ ++
Scoring of the intensity of the staining for fibulin-1, periostin and versican was performed as described in the “Methods” section. Cases in bold were analysed by
mass spectrometry (see Additional File 2). The asterisk indicates that the protein was also detected by mass spectrometry in the same sample.
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Proteins from the fibulin family participate in diverse
biological processes, including development, cancer, and
wound repair [18]. While in RLH, the antibody against
fibulin-1 produced only mild and focal staining of the
lymph node capsula, a strong staining of fibrous bands
and capsula was commonly observed in HL (12 out of
17 cases, Figure 3D). Some perivascular staining was
also present in HL.
Periostin
Periostin is a soluble heparin-binding N-glycosylated
ECM-associated protein that is thought to contribute to
cell adhesion and motility [19]. The antibody produced
weak to moderate reactivity in the capsula in reactive
lymph nodes and some perivascular staining (11 out of
15 RLH, Figure 3E). In HL, moderate to very strong
extracellular expression in capsula and fibrous bands
was observed (Figure 3F) in all cases (17 out of 17).
S100A8
Also known as Myeloid-Related Protein 8, this small
intracellular calcium-binding protein has also been
reported to be secreted, as well as expressed in the
ECM of prostate cancer [20]. We found that this protein
was also expressed in some parts of the ECM in both
reactive and cancer lymph nodes (Figure 3G and 3H).
The protein was found to be expressed by stromal cells,
but also by histiocytic/monocytic cells, as well as eosino-
phils and neutrophils.
Overall, overexpression in HL was clearly evident for
versican, fibulin-1 and periostin (Figure 4), with a glob-
ally consistent staining pattern for each case (Table 2).
Relationships between mass spectrometry and IHC for
these 3 differentially expressed proteins are summarized
in Additional File 3.
Discussion
Identification of stromal proteins specifically involved in
cancer is of considerable interest [21], since the “reactive
stroma” of desmoplastic reactions is thought to create a
permissive and supportive environment contributing to
cancer progression [22]. Moreover, stromal proteins that
are selectively expressed in cancer tissues are prime
Figure 2 Evaluation of the biotinylation efficiency. Thin slices of lymph nodes (in this case HL) were soaked in the biotinylation solution for
20 minutes at 37°C. Extent of tissue biotinylation was assessed using histochemistry, as described in Materials and Methods. Biotinylated tissue
was revealed with omission of the avidin reagent (A) and in the presence of avidin Vectastain-ABC reagent (B). Original magnification: ×100.
Table 3 Selection of biotinylated proteins identified in reactive lymphoid hyperplasia (RLH, n = 3) and Hodgkin
lymphoma (HL, n = 4)
Swiss Prot # Protein Name RLH (/3) SC HL (/4) SC Location Biological Process
P23142 Fibulin 1 0 0 2 3 EC Cell growth and/or maintenance
P13611 Versican 0 0 2 4 EC Cell growth and/or maintenance
P00488 Coagulation factor XIII A1 0 0 3 5 EC, C, N Metabolism, Transferase activity
P15531 Nucleoside diphosphate kinase A 1 3 3 7 C, N, EC, M Metabolism; Energy pathways
P11678 Eosinophil peroxidase 0 0 3 11 C, E Immune response
P02790 Hemopexin 0 0 4 17 E Transport
Q15063 Periostin, Osteoblast Specific Factor-2 1 3 4 51 EC Cell communication; Signal transduction
P05109 S100 Calcium binding protein A8 1 2 4 16 C, EC, PM Cell communication; Signal transduction
O43399 Tumor protein D52-L2 1 3 4 10 UK Unknown
The proteins are identified from the SwissProt database with Mascot. The numbers in bold indicate in how many runs each protein was detected. SC: Spectral
counting (italicized numbers represent the number of redundant spectra identifying the same protein or group of protein). Function and location of the proteins
is determined using the Human Protein Reference Database (http://www.hprd.org). C: cytoplasm, E: endosome, EC: extracellular, G: Golgi, M: mitochondrion, N:
nuclear, PM: plasma membrane, UK: unknown.
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they are expected to be more accessible than intracellu-
lar proteins, (ii) they are often present in high quantities
and iii) tumour ECM components are generally more
stable than tumour-associated cell surface antigens [23].
Considering that ~30% of patients experience relapse
and die of complications due to progressive disease and/
or treatment, the identification of proteins from HL
stroma could not only provide the basis for a better
understanding of the disease, but also lead to the
Figure 3 Validation by in situ expression analyses. Representative examples of versican (A and B), fibulin-1 (C and D), periostin (E and F) and
S100-A8 (G and H) expression in non-tumoural human reactive lymph nodes (A, C, E and G) and Hodgkin lymphoma (B, D, F and H), as
assessed by immunohistochemistry. Paraffin sections of human lymph nodes tissues were subjected to immunoperoxidase staining, as described
in Methods. Original magnification: ×50; insets (B, D and H): ×100.
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allowing earlier detection and treatment of relapsed and
refractory lymphoma by e.g. chemoprevention [24] or
antibody based anti-cancer treatments [25].
The clinical value of antibody-based targeted therapies
(targeting specifically the stroma) in HL patient has been
elegantly demonstrated in a recent study using a mono-
clonal antibody directed against the EDB alternative
spliced variant of fibronectin, known as L19 antibody
[26]. In light of these promising results, it is clear that the
discovery of novel accessible biomarkers in HL is a
necessary step to develop a large panel of targeting-based
therapies. Using a recently described chemical proteomic
method [15], we have identified potentially accessible
proteins that are of special interest for imaging technolo-
gies and targeted therapies in the Hodgkin’s disease. Our
method led to the identification of a total of 1431 pro-
teins in HL and RLH. We used mass spectrometry as a
screening tool, and only one two dimensional liquid
chromatography run was performed per sample. Analyti-
cal completeness was certainly not reasonably achievable
with one single 2D-LC run [27], but was not absolutely
necessary to unravel new potential biomarkers (the
assumption was made that a single run was likely to be
sufficient to detect the most abundant proteins, and the
quantitative aspect, despite analytical completeness
issues, was still helpful for biomarker selection). IHC was
the mandatory step to validate these potential biomar-
kers. Data obtained from mass spectrometry and IHC
experiments on identical samples are most of the time
consistent, but some discrepancies do exist (see Addi-
tional File 3). These differences can be explained by i)
analytical completeness of the mass spectrometry data as
stated above, ii) heterogeneity in the sample (one half
for mass spectrometry processing, one half for IHC
experiments) and iii) the specificity and sensitivity of
antibodies used in IHC experiments. Our mass spectro-
metry methodology and IHC are therefore rather com-
plementary techniques, and it can be foreseen that IHC
results would more likely compare to mass spectrometry
experiment such as MRM (Multiple Reaction Monitor-
ing) that could look specifically for versican, fibulin-1 and
periostin in each sample.
The complete list of identified proteins included extra-
cellular and plasma membrane proteins, but also include a
non-negligible fraction of intracellular proteins. The rea-
sons for this observation have already been discussed else-
where [15,28]. Focusing on ECM proteins, we identified
several proteins already known to be associated with
human HL. These proteins were consequently not further
validated by immunohistochemistry. For instance, hemo-
pexin protein was found elevated in the serum of patients
with HL [29]; eosinophil peroxidase has already been used
for radio-immunodetection of Hodgkin’sd i s e a s e[ 3 0 ] ;
coagulation factor XIII was found to be expressed by
macrophages and involved in the stabilization of fibrin
deposits in the tumour stroma of HL samples [31]; and
nucleoside diphosphate kinase A expression was found to
be a prognostic factor for classical HL [32].
We also identified proteins without direct relationship
with HL demonstrated in the literature. Among these pro-
teins, we showed that the extracellular proteins versican,
fibulin-1 and periostin were actually overexpressed in the
extracellular matrix after immunohistochemical analyses.
The staining pattern of expression was somewhat similar
for the 3 proteins in most HL samples tested. This result is
interesting, since the three proteins are expressed by dif-
ferent cells: versican is known to be expressed by fibro-
blasts and only rarely by cancer cells, fibulin-1 was shown
to be expressed mainly by cancer cells and only by some
fibroblasts [33], and periostin is expressed by both fibro-
blasts and cancer cells. Moreover the staining was mainly
specific to fibrosis. While only scarce information is avail-
able about versican in fibrosis, except in the lung [34]
(where it may influence early repair processes), fibulin-1
deposits were already reported in rat liver fibrosis [35].
Periostin, by altering the deposition and attachment of col-
lagen, is a critical regulator of fibrosis [36].
Among these three potential biomarkers, two of them,
namely versican and fibulin-1, were almost absent in RLH.
Although periostin displayed a very strong expression in
HL, this protein was indeed found expressed at lower
levels in RLH. It would be of interest to assess the serum
concentrations of each of these ECM proteins in patients
with HL in order to determine how valuable seric dosage
of these proteins may be for diagnostic purposes.
S100A8 was expressed in the ECM of both RLH and HL.
The protein was found to be expressed in cells of the
immune system (e.g. monocytes, eosinophils, neutrophils).
Figure 4 Relative expression of three extracellular proteins,
Versican, Fibulin-1, and Periostin, as determined by IHC in RLH (n =
15) and HL (n = 17). Bargraphs represent the mean scoring (0 to 3+,
determined as described in the “Material and Methods” section)
from Tables 1 and 2.
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increased expression of this protein in this diseased state
was expected. Results of mass spectrometry were anyway
confirmed for the four proteins tested in IHC.
Conclusion
To summarize, we identified several proteins overex-
pressed in the ECM of HL. The potential of these pro-
teins for the accurate diagnosis and staging of HL
deserves further investigations.
Methods
Tissue harvesting
Pieces of fresh human lymph nodes biopsies obtained
from the Pathology department were immediately sliced
and soaked into freshly prepared EZ-link Sulfo NHS-SS
biotin (1 mg.ml
-1, Pierce, Erembodegem-Aalst, Belgium)
for 20 min in PBS (pH 7.4) as previously described [15].
Tissue samples were then snap-frozen in liquid nitrogen,
except for a tiny portion of each sample that was directly
immersed in formalin and then processed for further his-
tological and histochemical investigations. Additional tis-
sue samples not included in the biotinylation procedure
were routinely processed for histopathological diagnosis.
Controls included adjacent tissue slices incubated in PBS.
Formalin-fixed, paraffin-embedded (FFPE) blocks of
additional cases of nodular sclerosis HL (n = 13) and var-
ious kinds of RLH (n = 12) were retrieved from the files
of the Pathology Department of the University Hospital
of Liège. For all cases, diagnostics were made according
to WHO classification criteria [1]. Clinico-pathological
data are reported in Tables 1 and 2. All cases were
reviewed by a haematopathologist (LdL). The Ethics
Committee of the University Hospital of Liege reviewed
and approved the specific protocol used in this study.
Histochemistry and immunohistochemistry
Tissue penetration of the biotinylation reagent and effi-
ciency of labelling were verified in FFPE lymph nodes tis-
sue sections. Slides were incubated with avidin-peroxidase
conjugates with the use of the Vectastain ABC kit (Vector
Labortories, Burlingame, CA, USA), according to the
manufacturer’s instructions. Immunohistochemical valida-
tion experiments were performed as previously described
[37]. For the immunohistochemical detection of versican,
antigen retrieval was performed by incubating the slides
with chondroitinase (Sigma-Aldrich, Bornem, Belgium).
Anti-versican (clone 12C5) was developed by R. Asher,
and obtained from the Developmental Studies Hybridoma
Bank (University of Iowa, Department of Biological
Sciences, Iowa City). This antibody was applied onto the
sections at a dilution of 1:200. Anti-Fibulin-1 is an affinity
isolated rabbit antibody purchased from Sigma. The
immunoaffinity-purified rabbit polyclonal anti-periostin
antibody was purchased from Biovendor (Heidelberg,
Germany). S100-A8 (Calgranulin A) is an affinity purified
goat polyclonal purchased from Santa-Cruz (Heidelberg,
Germany). Control experiments included omission of the
primary antibody in the procedure. Scoring of the intensity
of the staining was performed as described previously [37],
according to an arbitrary scale with steps of -, -/+, +, ++,
and +++, where “-” was considered to be no detectable
staining, “-/+” consisted in mild, focal staining, “+” was
considered as weak positive staining, “++” represented
moderate staining, and “+++” was considered to be strong
staining.
Sample processing
Processing was performed as previously described [15],
with minor modifications. Briefly, pulverization of frozen
biotinylated tissues was performed using a Mikro-Dis-
membrator U (Braun Biotech, Melsungen, Germany) and
generated tissue powder. Approximately 100 mg of tissue
powder was resuspended first in a PBS buffer containing
a protease inhibitor cocktail (Halt™, Pierce). Homoge-
nates were sonicated (2 × 30”) with a 2 mm microprobe
and soluble proteins were subjected to a preclearing step
consisting in human serum albumin (HSA) and immuno-
globulins (IgGs) depletion (Qproteome HSA and IgGs
Removal Kit, Quiagen, Hilden, Germany). This step was
included to limit the number of HSA and IgGs peptides
detected by mass spectrometry (MS). Insoluble pellet was
resuspended in RIPA buffer, and lysates were sonicated
(2 × 30”), centrifuged, and further depleted in HSA and
IgGs. The insoluble pellet was finally dissolved in 2%
SDS. HSA- and IgGs-depleted proteins fraction and SDS-
solubilized proteins were pooled and boiled for 5 min-
utes. Efficiency of HSA and IgG depletion was checked
by SDS-PAGE and coomassie blue staining. Biotinylated
proteins were then captured on a streptavidin resin (100
μl per mg of total proteins, Pierce), washed in buffer A
(1% NP40 and 0.1% SDS in PBS). Protein binding was
allowed for 2 hours at room temperature in a rotating
mixer. After thorough washes to remove abundant cyto-
solic proteins with high salt buffer (buffer B: 0.1% NP40,
1 M NaCl in PBS), high pH buffer (0.1 M sodium carbo-
nate in PBS, pH 11), and PBS. The proteins were then
eluted thanks to the disulfide bonds between the lysines
of labelled proteins and the biotin moieties (30’ incuba-
tion steps in 1% SDS, 100 mM DTT at 58°C), allowing to
bypass the direct on-resin (and thus streptavidin) diges-
tion. Proteins were alkylated with iodoacetamide during
30’ in the dark. The eluted proteins were then precipi-
tated with 15% TCA overnight. Binding of the biotiny-
lated proteins onto the resin and washing efficiencies
were checked after SDS-PAGE, either by Coomassie blue
staining or by blotting for subsequent detection of biotin
by streptavidin-horseradish peroxidase (data not shown).
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Peptide separation by reverse-phase liquid chromatogra-
phy was performed on an Ultimate LC system (LC Pack-
ings, now Dionex) completed by a Famos autosampler
and a Swichos II Microcolumn switching device for sam-
ple clean-up, fractionation and preconcentration. Sample
(5 μgi n2 0μla t0 . 2 5μg/μl 0.1% formic acid) was first
trapped on a SCX micro pre-column (500 μMi n t e r n a l
diameter, 15 mm length, packed with MCA50 bioX-SCX
5 μm; LC Packings, now Dionex) at a flow rate of 200 nl.
min
-1 followed by a micro pre-column cartridge (300 μM
i.d., 5 mm length, packed with 5 μm C18 PepMap100; LC
Packings, now Dionex). After 5 minutes, the precolumn
was connected with the separating nanoflow column
(75 μm i.d., 15 cm length, packed with 3 μmC 1 8P e p -
MAp100; LC Packings, now Dionex) equilibrated in
mobile phase A (0.1% formic acid in 2:98 of acetonitrile:
degassed milliQ water). A linear elution gradient was
applied with mobile phase B (0.1% formic acid in 80:20 of
acetonitrile:degassed milliQ water) spanning from 10% to
40% in 95 minutes. The outlet of the LC system was
directly connected to the nano electrospray source of an
Esquire HCT Ultra ion trap mass spectrometer (Bruker
Daltonics, Germany), controlled by Esquire Control v6.1,
build 92 and Hystar v3.2, build 44 (from the Bruker
Compass software bundle). Mass data acquisition was
performed in the mass range of 50-2000 m/z using the
standard-enhanced mode (8100 m/z per second). For
each mass scan, a data-dependent scheme picked the 3
most intense doubly or triply charged ions to be selec-
tively isolated and fragmented in the trap. The resulting
fragments were analysed using the Ultra Scan mode (m/z
range of 50-3000 at 26000 m/z per second). SCX-trapped
peptides were stepwise eluted with 4 CH3COONH4 con-
centrations, each followed by the same gradient of mobile
phase B.
Data processing and mgf file generation
Raw spectra were formatted in DataAnalysis software (Bru-
ker Daltonics, v3.4 build 192). The portions of the 4 chro-
matograms (resulting from the 4 elutions with 25 mM, 75
mM, 150 mM and 500 mM CH3COONH4) containing sig-
nal (i.e. with base peak chromatogram signal above 5000
arbitrary units) were processed to extract and deconvolute
MS/MS spectra, without smoothing or background sub-
traction. A signal/noise ratio of 3 was applied to filtrate
irrelevant data in the MS/MS spectra and generate the
mass list. Charge deconvolution was performed on both
MS and MS/MS spectra. A retention time of 2 minutes
was allowed for compound elution to minimize detection
redundancy of parents of identical masses and charge
states. Both deconvoluted and undeconvoluted data were
incorporated in the mgf file.
Database Searching
Proteins were identified using the minimally redundant
SWISS-PROT human protein database (release 54.5,
289473 sequences, SIB; Switzerland, 17741 human
entries), through the MS/MS ion search algorithm of
the Mascot search engine (Mascot Server v2.1.04 and
Mascot Daemon v2.1.6) running on a local 4-processor
computer cluster. The mass tolerances of precursor and
fragmented ions were set at 0.6 and 0.3 Dalton respec-
tively; variable modifications were carboxymethyl
cysteines and oxidization of methionines. Trypsin cuts
before proline were allowed, and one misscut was also
allowed. The ions score cut-off was set to 30. The abso-
lute probability (P) was set to 0.05 (i.e. less than 5%
probability of a random match). The full protein list
generated with the above-mentioned parameters con-
tained 1431 proteins (Additional File 2).
The false-positive rate was estimated, for each sample,
by dividing the number of peptides found in the rando-
mised SwissProt database by the number of identified pep-
tides from the normal SwissProt database, according to
following formula: fp = n random/n normal, where fp is
the estimated false-positive rate, n random is the number
of peptides identified (queries after filtering) from the ran-
dom SwissProt database, and n normal is the number of
peptides identified (queries after filtering) from the normal
SwissProt database. Considering the 8 samples, fp is equal
to 1.94 ± 0.15% (Mean ± SEM).
Additional material
Additional file 1: Distribution of proteins identified in reactive
lymphoid hyperplasia (RLH) samples and Hodgkin Lymphoma (HL)
samples. Pie charts illustrating the distribution of proteins identified in
reactive lymphoid hyperplasia (RLH) samples and Hodgkin Lymphoma (HL)
samples.
Additional file 2: Proteins identified in Reactive Lymphoid
Hyperplasia (RLH) and Hodgkin Lymphoma (HL). List of proteins
identified in 3 Reactive Lymphoid Hyperplasia (RLH) and 4 Hodgkin
Lymphoma (HL) by nanoLC-ESI-MS/MS analyses.
Additional file 3: Relationships between mass spectrometry and IHC
for 4 differentially expressed proteins. Table showing relationships
between mass spectrometry and IHC for 4 differentially expressed proteins.
Abbreviations
ECM: extracellular matrix; MudPIT: Multidimensional protein identification
technology; NHS: N-hydroxy-succinimid; RT: Room Temperature
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